A Phase 2A, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Two Dose Levels of Mitoglitazone in Type 2 Diabetic Patients.

Trial Profile

A Phase 2A, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Two Dose Levels of Mitoglitazone in Type 2 Diabetic Patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 May 2013

At a glance

  • Drugs MSDC 0160 (Primary) ; Pioglitazone
  • Indications Type 2 diabetes mellitus
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 18 Oct 2009 Results presented at the 20th World Diabetes Congress (WDC).
    • 14 May 2009 Nearly 100 patients have been enrolled, according to a Metabolic Solutions Development Company media release.
    • 14 May 2009 Positive preliminary results reported in Metabolic Solutions Development Company media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top